Article

Othera begins phase I/II trial of glaucoma drug

Othera Pharmaceuticals Inc. has begun dosing in a phase I/II multicenter, investigator-masked clinical trial of the safety and efficacy of a topical drug (OT-730) in reducing IOP in subjects with ocular hypertension or open-angle glaucoma

Exton, PA—Othera Pharmaceuticals Inc. has begun dosing in a phase I/II multicenter, investigator-masked clinical trial of the safety and efficacy of a topical drug (OT-730) in reducing IOP in subjects with ocular hypertension or open-angle glaucoma. Subjects will be assigned randomly to receive the 0.75% formulation of the investigational drug, 0.5% timolol maleate, or placebo.

The drug being studied is a novel, next-generation, topical, beta-blocker designed to lower IOP. In preclinical animal studies, it demonstrated comparable IOP-lowering efficacy and superior systemic safety versus the most-prescribed ocular beta-blocker, timolol maleate, according to the company. By design, the medication is an oculoselective drug that offers beta-blocking activity in the eye while being metabolized easily into inert components on entry into the bloodstream, according to the company.

“It is well-accepted in the ophthalmic community after over 30 years of experience that beta-blockers are successful in lowering IOP. The relative market share of beta-blockers has declined, however, in large part due to safety issues,” said David Joseph, Othera chief executive officer and chairman. “We have surveyed a number of glaucoma key opinion leaders, and nearly all told us that they would initially prescribe a beta-blocker if it were effective and did not produce the systemic side effects typically seen with this class of drugs. Our compound’s unique chemistry enables a clinical development plan emphasizing improved safety and provides the support needed for [the drug] to be a successful product in a growing, age-related market.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.